Encision Reports Third Quarter Fiscal Year 2025 Results: A Period of Transition and Growth

Encision Inc. (OTC PINK:ECIA), a medical device company specializing in patented Active Electrode Monitoring (AEM®) Technology, recently reported its fiscal 2025 third quarter results, marking a period of transition and growth for the company. The quarter, which ended on December 31, 2024, saw Encision post total net revenue of $1.59 million, comprising $1.46 million in product net revenue and $128 thousand in service net revenue. This resulted in a quarterly net loss of $24 thousand, or $(0.00) per diluted share.



The company's gross margin on product net revenue improved to 54% in the fiscal 2025 third quarter, up from 46% in the fiscal 2024 third quarter. This improvement can be attributed to higher operating efficiencies and increased selling prices. Encision's president and CEO, Gregory Trudel, stated that the third quarter was a rebuilding period for the company, as it brought additional sales partners online, but their contributions to the top line were insufficient. During this period, Encision implemented enhancements to reduce internal costs, the effects of which will be evident beginning in Q4.



Encision's nine-month product net revenue for the fiscal 2025 period was $4.7 million, with a gross margin of 52.7%. This compares to $4.93 million and a gross margin of 48.5.7% in the fiscal 2024 nine months. The company's nine-month net loss for the fiscal 2025 period was $172.9 thousand, or $(0.01) per diluted share, compared to a net loss of $355 thousand, or $(0.03) per diluted share, in the fiscal 2024 nine months.

Encision is developing a new product for ENT surgery, expected to launch in the first half of FY2026. This new product aligns with the company's strategic goals and potential market demand, as it expands Encision's reach into a new market segment and leverages its existing AEM technology. The global ENT market is expected to grow at a CAGR of 5.5% during the forecast period (2021-2028), driven by factors such as an increasing prevalence of ENT disorders, technological advancements, and a growing geriatric population (Fortune Business Insights, 2021).

In conclusion, Encision's fiscal 2025 third quarter results reflect a period of transition and growth for the company, with improved gross margins and a focus on internal cost reduction measures. The company's new product for ENT surgery, expected to launch in the first half of FY2026, aligns with its strategic goals and potential market demand. As Encision continues to execute on its strategic initiatives, investors should monitor the company's progress and consider the potential opportunities that lie ahead.

Sources:
- Encision Inc. (2025). Encision Reports Third Quarter Fiscal Year 2025 Results. Retrieved from
- Fortune Business Insights™ (2021). ENT Market Size, Share & COVID-19 Impact Analysis - By Product (Endoscopes, Surgical Instruments, and Others), By Application (Diagnostic and Therapeutic), By End User (Hospitals, Ambulatory Surgical Centers, and Others), and Regional Forecast, 2021-2028. Retrieved from